Equillium, Inc. (NASDAQ:EQ)
| Market Cap | 133.41M+6.0% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -18.01M+10.8% |
| EPS | -0.26+54.2% |
| Shares Out | 63.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 552,064 |
| Open | 2.46 |
| Previous Close | 2.42 |
| Day's Range | 2.11 - 2.46 |
| 52-Week Range | 0.76 - 3.54 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 6.25(+196.21%) |
| Earnings Date | Nov 12, 2026 |
About EQ
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
$EQ stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EQ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EQ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EQ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EQ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EQ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EQ
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.08M |
| VXFVanguard Extended Market ETF | $821.41K |
| IWCiShares Micro-Cap ETF | $391.87K |
| AVSCAvantis U.S. Small Cap Equity ETF | $182.49K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $95.04K |
| DFASDimensional - US Small Cap ETF | $18.55K |
Estimated from each fund’s disclosed top holdings × AUM
EQ Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EQ’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.